1-9 of 9
Frederik Lersch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

Khaled M. Musallam, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Bueno, Jeevan K. Shetty, Frederik Lersch, Barbara Rosettani, Maria Domenica Domenica Cappellini
Journal: Blood
Blood (2022) 140 (Supplement 1): 5358–5359.
https://doi.org/10.1182/blood-2022-157113
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos
Journal: Blood
Blood (2021) 138 (Supplement 1): 1244.
https://doi.org/10.1182/blood-2021-147601
Published: 2021
Journal Articles

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James K McCloskey, Olatoyosi Odenike, Bob Lowenberg, Gert J. Ossenkoppele, Prapti Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Salah Nabhan, Caroline Almon, Duygu Saatcioglu, Vickie Zhang, Michael Cooper, Hagop Kantarjian, Martin S. Tallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1276.
https://doi.org/10.1182/blood-2021-146507
Published: 2021
Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James K. McCloskey, Olatoyosi Odenike, Bob Löwenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Aleksandra Franovic, Salah Nabhan, Bin Fan, Sung Choe, Hongfang Wang, Bin Wu, Lei Hua, Caroline Almon, Michael Cooper, Hagop M. Kantarjian, Martin S. Tallman
Journal: Blood
Blood (2021) 137 (13): 1792–1803.
https://doi.org/10.1182/blood.2020007233
Published: 2021
Includes: Supplemental data
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Amir T. Fathi, MD, Alice S. Mims, MD, Keith W. Pratz, MD, Michael R. Savona, MD, Anthony S. Stein, MD, Richard M. Stone, MD, Eric S. Winer, MD, Christopher S. Seet, MD, Hartmut Döhner, MD, Daniel A Pollyea, MD, James K McCloskey, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD, Gert J. Ossenkoppele, MD PhD, Prapti A. Patel, MD, Mikhail Roshal, MD PhD, Frederik Lersch, RN, Salah Nabhan, MS, Sung Choe, PhD, Hongfang Wang, PhD, Lei Hua, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 560.
https://doi.org/10.1182/blood-2018-99-110449
Published: 2018
Journal Articles

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Katja Weisel, MD, Meletios A Dimopoulos, Niels W.C.J. van de Donk, MD PhD, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld
Journal: Blood
Blood (2016) 128 (22): 3311.
https://doi.org/10.1182/blood.V128.22.3311.3311
Published: 2016
Journal Articles

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt-Hieber, Marie-Christiane Vekemans, Ángel Ramírez Payer, Pal Tore Bentsen, Birgitta Lauri, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Torben Plesner, Professor
Journal: Blood
Blood (2016) 128 (22): 5680.
https://doi.org/10.1182/blood.V128.22.5680.5680
Published: 2016
Journal Articles

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Karthik Ramasamy, Meletios A. Dimopoulos, Niels W.C.J. van de Donk, Barbara Gamberi, Frank Bridoux, Matthew Streetly, Elisabeth Kueenburg, Barbara Rosettani, Shona Collins, Frederik Lersch, Pamela Bacon, Katja C. Weisel, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2015) 126 (23): 374.
https://doi.org/10.1182/blood.V126.23.374.374
Published: 2015